Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Journal of Translational Medicine

Figure 4

From: Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice

Figure 4

All three agonist antibodies are necessary in combination with IL-2 for optimal anti-tumor effects. Following intrakidney injection of Renca cells, mice received the treatments listed as indicated by arrows. Some mice received the complete treatment of Tri-mAb + IL-2, whereas other groups received various pairs of antibodies as listed either alone or in combination with IL-2. Some mice received no treatment to act as controls. Numbers in parentheses depict number of mice per group. Results from a single experiment, P < 0.05 for three antibodies + IL-2 vs two antibodies + IL-2 (Log-rank test), except for the comparison between Tri-mAb + IL-2 and MD5.1/CD40 + IL-2 which tended towards significance at P = 0.079.

Back to article page